INVVY - Indivior: A Compelling Litigation Story

• Indivior stock was down 30% on a baseless preliminary claim filed by Indivior’s former parent company Reckitt Benckiser.
• Reckitt’s claim is procedurally defective and substantively precluded due to Reckitt’s alleged acts of fraud or dishonesty.
• As the leader in opioid treatment medications, Indivior’s business is growing rapidly, with 20% QoQ growth for leading drug Sublocade.
• Once the litigation clouds are removed, the market will finally recognize Indivior’s massive potential, with 30%-40% upside potential near term and over 100% within a year.

For further details see: